Latest Breaking News On - Tellus bioventures - Page 5 : vimarsana.com

Published: May 18, 2021 By Alex Keown Three companies on three separate continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.  Hummingbird Bioscience Raises $125 Million Singapore-based  raised $125 million in an oversubscribed Series C financing round. The funds will be used to support the development of the company’s two lead programs and advance its early-stage clinical research.  Hummingbird’s two lead assets are HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, a first-in-class anti-VISTA neutralizing antibody for advanced solid tumors.  The funds will also be used to expand the capabilities of Hummingbird s proprietary Rational Antibody Discovery platform and progress the development of its next-generation pipeline of precision therapeutics, including HMBD-009, a BCMA-TACI dual-specific T cell engager. 

United statesFrance generalPureos bioventuresRudolphe basserveTellus bioventuresBain capital life sciencesPiggy bank moneyOsage university partnersSk incMark foundation for cancer researchUniversity of pennsylvaniaLongwood fundAmerican cancer societyPiggy bankBioscience raisesHummingbird bioscienceraised